Decreased programmed cell death ligand 2-positive monocytic myeloid-derived suppressor cells and programmed cell death protein 1-positive T-regulatory cells in patients with type 2 diabetes: implications for immunopathogenesis [PDF]
Endocrine Connections, 2023 Objectives: The activation of immune cells plays a significant role in the progression of type 2 diabetes. This study aimed to investigate the potential role of myeloid-derived suppressor cells (MDSCs) and T-regulatory cells (Tregs) in type 2 diabetes.
Zhaoxiang Liu +7 more
doaj +4 more sources
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Translational Oncology, 2020 Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results.
Cinzia Solinas +5 more
doaj +2 more sources
Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study
Surgery Open Science, 2021 Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy.
Nicholas J. Skertich, MD +5 more
doaj +1 more source
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
BMC Cancer, 2022 Background Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL.
Fereshteh Ameli +3 more
doaj +1 more source
Frontiers in Oncology, 2022 Immune checkpoint inhibitor (ICI)-induced colitis is one of the known complications of therapies targeting cytotoxic programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death ligand 1 (PD-L1).
Leilei Fang +3 more
doaj +1 more source
A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient
Cell Death Discovery, 2023 Triple-negative breast cancer (TNBC) is the most aggressive subtype of mammary carcinoma. Here, we describe a case of an 81-year-old female diagnosed with ductal triple negative breast cancer with a germline pathogenic variant in BReast CAncer gene2 ...
Yuyi Han +12 more
doaj +1 more source
T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
Journal for ImmunoTherapy of Cancer, 2021 Cancer immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of numerous cancer types. As the underlying mechanism of these treatments lies in the interference with inhibitory signals that usually impair potent ...
Dirk Baumjohann, Peter Brossart
doaj +1 more source
Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer
Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020 Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan +3 more
doaj +1 more source
JTO Clinical and Research Reports, 2021 Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2)
Nobukazu Fujimoto, MD, PhD +10 more
doaj +1 more source
Animal Models and Experimental Medicine, 2021 Programmed cell death protein 1 (PD‐1) /programmed cell death ligand 1 (PD‐L1) blockade is an important therapeutic strategy for melanoma, despite its low clinical response.
Yuchen Wang +3 more
doaj +1 more source